Eltrombopag combined with immunosuppressive therapy in pediatric patients with severe aplastic anemia achieved a 54.9% overall response rate at 26 weeks, with a 71.4% response in relapsed/refractory ...

Please provide your email address to receive an email when new articles are posted on . Prior trials established the role of haploidentical BMT for severe aplastic anemia. Two trials underway have the ...

Aplastic anaemia is a very rare but life-threatening condition of the bone marrow that can lead to death within months if not appropriately managed. In this condition where the bone marrow fails to ...

Dec. 8 (UPI) --The U.S. Food and Drug Administration on Monday announced the approval of the first hematopoietic stem cell transplant therapy to treat patients with rare but severe aplastic anemia.